Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. Patients with chronic lymphocytic leukemia (CLL) that develop resistance to Bruton tyrosine kinase (BTK) inhibitors are typically positive for mutations in BTK or phospholipase c gamma 2 (PLCγ2). We developed a high sensitivity (HS) assay utilizing wild-type blocking polymerase chain reaction achieved via bridged and locked nucleic acids. We used this high sensitivity assay in combination with Sanger sequencing and next generation sequencing (NGS) and tested cellular DNA and cell-free DNA (cfDNA) from patients with CLL treated with the BTK inhibitor, ibrutinib. […]
Why not Stay in Touch…?
- Time Matters on Health Tests [TAT-NGS]
- Myelodysplastic Syndrome (MDS)
- Genomic Testing Cooperative Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms
- Comprehensive PIK3CA Mutation Analysis
- The FDA has Approved Drugs for FGFR Abnormalities
acute myeloid leukemia Adult AI AML apoptosis B-Cell Lymphoma beta 2-Microglobulin Biological Biological Processes Biomarkers bone marrow BTK Case Study chemotherapy Clinically relevant CLL Congress Diseases DNA profiling enzyme inhibitors genetic profiling genomic testing gtc hematology ibrutinib Janus Kinase 2 Ki-67 Antigen leukemia liquid biopsy Lymphoid Malignancies Myeloid Malignancies ngs Non-Biological PLCγ2 press release Receptors resistance RNA sequencing signal transduction Study Population Technology and Procedures Therapies Thrombopoietin TKI Young Adult